28/APR/12

Neuron BioPharma explains in Salamanca the advances in its research into the neuroprotective compound NST 0037

The CSO of the Neuron BioPharma division of Neuron Bio, Javier S. Burgos, gave a talk in Salamanca on 25 April during a seminar at the Instituto de Neurociencias de Castilla y León (The Institute of Neurosciences of Castilla and Leon), in which he described the advances in research made by this pharmaceuticals division of the company, focusing particularly on its research into the compound NST 0037, which shows neuroprotective capacity.

Dr Burgos gave a speech entitled, “Developing a new statin to prevent Alzheimer’s disease”, in which he explained Neuron BioPharma’s line of research, which has demonstrated that statins (drugs that reduce cholesterol levels) are able to prevent the neurodegeneration associated with Alzheimer’s disease. As a result of its research so far, Neuron BioPharma has developed and patented a new statin that decreases cholesterol levels in the blood, prevents neuron death and protects against loss of memory.

The seminar was organised by the International Campus of Excellence of the University of Salamanca to strengthen the relationship between universities and companies in the field of biotechnology.